Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer. (Q38937813)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

title

Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

18

Stefan Endres

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Sebastian Kobold

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Julius Steffen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Michael Chaloupka

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Simon Grassmann

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Jonas Henkel

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Raffaella Castoldi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Yi Zeng

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Markus Chmielewski

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Jan C Schmollinger

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Max Schnurr

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Simon Rothenfußer

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Dolores J Schendel

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Hinrich Abken

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Claudio Sustmann

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Gerhard Niederfellner

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Christian Klein

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

language of work or name

English

0 references

publication date

24 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

Journal of the National Cancer Institute

23 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

364

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

Adoptive immunotherapy for cancer: harnessing the T cell response

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, re-filling of the lytic granules and secretion of lytic proteins via a non-granule pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

Protective capacity of virus-specific T cell receptor-transduced CD8 T cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

Efficient eradication of subcutaneous but not of autochthonous gastric tumors by adoptive T cell transfer in an SV40 T antigen mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

Trastuzumab-associated cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

Preliminary trial of specific targeting therapy against malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

Quantification of cell surface proteins with bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU364

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJU364

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25424197%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference